| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | Exit | Allergan PLC | $0 | – | -3,347 | -100.0% | -0.47% | – |
| ANAB | Exit | AnaptysBio Inc | $0 | – | -12,026 | -100.0% | -0.57% | – |
| GILD | Exit | Gilead Sciences Inc | $0 | – | -18,697 | -100.0% | -1.05% | – |
| DERM | Exit | Dermira Inc | $0 | – | -138,102 | -100.0% | -1.10% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Inc | $0 | – | -15,423 | -100.0% | -1.35% | – |
| REGN | Exit | Regeneron Pharmaceuticals Inc | $0 | – | -5,668 | -100.0% | -1.48% | – |
| ITCI | Exit | Intra-Cellular Therapies Inc | $0 | – | -143,665 | -100.0% | -1.55% | – |
| MYL | Exit | Mylan NV | $0 | – | -102,560 | -100.0% | -1.63% | – |
| BHVN | Exit | Biohaven Pharmaceutical Holdin | $0 | – | -86,165 | -100.0% | -3.14% | – |
| ABBV | Exit | AbbVie Inc | $0 | – | -52,681 | -100.0% | -3.19% | – |
| AMRN | Exit | Amarin Corp PLCspons adr new | $0 | – | -230,295 | -100.0% | -3.72% | – |
| QURE | Exit | uniQure NV | $0 | – | -59,883 | -100.0% | -3.90% | – |
| URGN | Exit | UroGen Pharma Ltd | $0 | – | -176,866 | -100.0% | -5.30% | – |
| PCRX | Exit | Pacira BioSciences Inc | $0 | – | -149,086 | -100.0% | -5.40% | – |
| ASND | Exit | Ascendis Pharma A/Ssponsored adr | $0 | – | -60,266 | -100.0% | -5.78% | – |
| CHRS | Exit | Coherus Biosciences Inc | $0 | – | -316,316 | -100.0% | -5.82% | – |
| IMMU | Exit | Immunomedics Inc | $0 | – | -524,140 | -100.0% | -6.06% | – |
| GBT | Exit | Global Blood Therapeutics Inc | $0 | – | -142,305 | -100.0% | -6.23% | – |
| SRPT | Exit | Sarepta Therapeutics Inc | $0 | – | -50,317 | -100.0% | -6.37% | – |
| NBIX | Exit | Neurocrine Biosciences Inc | $0 | – | -92,380 | -100.0% | -6.50% | – |
| BOLD | Exit | Audentes Therapeutics Inc | $0 | – | -294,013 | -100.0% | -9.27% | – |
| INSM | Exit | Insmed Inc | $0 | – | -470,741 | -100.0% | -10.04% | – |
| ICPT | Exit | Intercept Pharmaceuticals Inc | $0 | – | -152,441 | -100.0% | -10.10% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.